0:00
27:40
In this episode, we welcome the lead author of “Deucravacitinib, a Tyrosine Kinase 2 Inhibitor, in Systemic Lupus Erythematosus: A phase 2, Randomized, Double-Blind, Placebo-Controlled Trial” Dr. Eric Morand of Monash University. The objective of this multicenter clinical trial in lupus (recently published in “Arthritis & Rheumatology”) was to assess the efficacy of deucravacitinib in a phase II trial in adult patients with active lupus. Dr. Morand’s methods, results and ultimate conclusions take center stage of our show today.
More episodes from "ACR Journals On Air"
Don't miss an episode of “ACR Journals On Air” and subscribe to it in the GetPodcast app.